Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
50.00    -1.00 (-1.96%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £95.93m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Directors' Disclosure

29 Nov 2013 07:00

RNS Number : 2260U
Iofina PLC
29 November 2013
 



29 November 2013

 

Iofina plc

("Iofina" or the "Company")

(LSE AIM: IOF)

 

Directors' Disclosure

 

Iofina, specialists in the exploration and production of iodine and iodine specialty chemical derivatives, announces a change in the beneficial ownership in the share capital of the Company for George Lantz, Chief Executive Officer, and Jeff Ploen, Non-Executive Deputy Chairman.

 

J. Paul Consulting, Inc. (a company in which Jeff Ploen has the sole beneficial interest) has granted to Mr Lantz 125,000 options over such number of ordinary shares in the capital of the Company held by J. Paul Consulting, Inc. with an exercise price per share of £1.51, being the closing share price on the day Mr Lantz joined the Company, with 33.3% of such options vested at grant date, and 33.3% to vest at each of 19 September 2014 at 19 September 2015.

 

Lance Baller, the former Chief Executive Officer of IOF, has granted to Mr Lantz 125,000 options over such number of ordinary shares in the capital of the Company held by Mr Baller with an exercise price per share of £1.51, being the closing share price on the day Mr Lantz joined the Company, with 33.3% of such options vested at grant date, and 33.3% to vest at each of 19 September 2014 at 19 September 2015.

 

Following the grant of options the revised holdings of Mr Lantz and Mr Ploen are set out below:

 

Director

Number of Shares

% of issued share capital

Total Number of Shares Under Option

Exercise Price

George Lantz

26,433

0.02

500,000

151p

Jeff Ploen

9,400,000*

7.39

Nil

* Includes 1,200,000 Shares held by J Paul Consulting, Inc.

 

Each of J Paul Consulting, Inc. and Lance Baller is prohibited from selling the aforementioned number of shares as are required to satisfy their undertaking to Mr Lantz. The Company is not a party to the arrangements agreed between Mr Ploen, Mr Baller and Mr Lantz respectively, both of which are private transactions agreed between them.

 

 

For further information, please contact:

 

Gary Gatchell, Finance DirectorTel: +44 (0) 20 3006 3135Simon Holden, Company SecretaryTel: +44 (0) 7800 500 097

Iofina plcwww.iofina.com 

 

Ben Colegrave/Chris Sim/James Rudd

Investec

Tel: +44(0)20 7597 5970

 

Media Contact:

Dominic Barretto/Anna Legge

Yellow Jersey PR Limited

Tel: +44(0) 7768 537 739

 

About Iofina

 

Iofina specializes in the exploration and production of iodine, iodine specialty chemical derivatives, produced water and natural gas. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America based on Iofina's WET® IOsorb™ technology. Iofina has iodine production operations in the United States, specifically in Texas, California, Montana, Oklahoma and Wyoming. The Group has complete vertical integration from the production of iodine in the field to the manufacture of the chemical end products derived from iodine to the consumer and the recycling of iodine using iodinated side-streams from waste chemical processes in Europe, North America and Asia. The Group utilizes its portfolio of patented and patent pending technology, proprietary methods and trademarks throughout all business lines.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUWSNROUAAUAA
Date   Source Headline
20th May 20197:00 amRNSProposed Placing and Open Offer
14th May 20197:00 amRNSStatement regarding share price rise
1st May 20197:00 amRNSFinal Results
17th Apr 20197:00 amRNSQ1 2019 Market Update
1st Apr 20197:00 amRNSCompletion of Debt Restructuring
22nd Feb 20194:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:35 pmRNSPrice Monitoring Extension
12th Feb 20197:00 amRNSDebt Restructuring
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
22nd Jan 20197:00 amRNSChange of Registered Office
17th Jan 20197:00 amRNSMarket Update
20th Nov 20184:40 pmRNSSecond Price Monitoring Extn
20th Nov 20184:35 pmRNSPrice Monitoring Extension
16th Nov 20187:00 amRNSDirector Appointment
18th Oct 20184:40 pmRNSSecond Price Monitoring Extn
18th Oct 20184:35 pmRNSPrice Monitoring Extension
10th Oct 20187:00 amRNSQ3 2018 Update
20th Sep 20187:00 amRNSInterim Results
16th Jul 20187:00 amRNSH1 2018 Update
18th Jun 20187:00 amRNSMarket update
14th Jun 20187:00 amRNSGrant of Options
13th Jun 201811:30 amRNSResult of AGM
30th Apr 20187:00 amRNSFinal Results and Notice of AGM
18th Apr 20187:00 amRNSQ1 2018 Market Update
16th Apr 20181:30 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
11th Apr 20186:20 pmRNSHolding(s) in Company
20th Mar 20183:05 pmRNSHolding(s) in Company
15th Mar 20181:24 pmRNSHolding(s) in Company
14th Feb 20187:00 amRNSProduction commences at IO#7
30th Jan 20183:00 pmRNSHolding(s) in Company
15th Jan 20187:00 amRNSMarket Update
14th Dec 20177:00 amRNSMarket Update
16th Nov 20177:00 amRNSIO#7 Progress and Market Update
20th Oct 20174:40 pmRNSSecond Price Monitoring Extn
20th Oct 20174:35 pmRNSPrice Monitoring Extension
10th Oct 20177:00 amRNSQ3 2017 Market Update
22nd Sep 20177:00 amRNSInterim Results
12th Sep 20177:00 amRNSConstruction of IO#7 to Expand Iodine Production
14th Jul 20177:00 amRNSCorporate and Production Update
14th Jun 201712:15 pmRNSResult of AGM
13th Jun 201712:07 pmRNSSecond Price Monitoring Extn
13th Jun 201712:02 pmRNSPrice Monitoring Extension
8th Jun 201712:07 pmRNSSecond Price Monitoring Extn
8th Jun 201712:02 pmRNSPrice Monitoring Extension
7th Jun 201712:07 pmRNSSecond Price Monitoring Extn
7th Jun 201712:02 pmRNSPrice Monitoring Extension
6th Jun 201712:07 pmRNSSecond Price Monitoring Extn
6th Jun 201712:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.